In both animals and plants, many developmentally important regulatory genes have complementary microRNAs (miRNAs), which suggests that these miRNAs constitute a class of developmental signalling molecules. Leaves of higher plants exhibit a varying degree of asymmetry along the adaxial/abaxial (upper/lower) axis. This asymmetry is specified through the polarized expression of class III homeodomain/leucine zipper (HD-ZIPIII) genes. In Arabidopsis, three such genes, PHABULOSA (PHB), PHAVOLUTA (PHV) and REVOLUTA (REV), are expressed throughout the incipient leaf, but become adaxially localized after primordium emergence. Downregulation of the HD-ZIPIII genes allows expression of the KANADI and YABBY genes, which specify abaxial fate. PHB, PHV and REV transcripts contain a complementary site for miRNA165 and miRNA166, which can direct their cleavage in vitro. Here we show that miRNA166 constitutes a highly conserved polarizing signal whose expression pattern spatially defines the expression domain of the maize hd-zipIII family member rolled leaf1 (rld1). Moreover, the progressively expanding expression pattern of miRNA166 during leaf development and its accumulation in phloem suggests that miRNA166 may form a movable signal that emanates from a signalling centre below the incipient leaf.
Background/Aims: The JAK2V617F mutation, which has been found in patients with myeloproliferative disorders (MPD), has not yet been evaluated in lymphoproliferative disor- ders by any adequately sensitive techniques. Methods: We investigated whether low levels of JAK2V617F are present in lymphoid neoplasms using a highly sensitive and highly specific amplification refractory mutation system PCR (ARMS-PCR) assay. Results: While 234 of 237 cases did not carry the JAK2V617F allele, it was identified in the bone marrow of 3 B cell lymphoma patients. The mutation was found to be neither associated with the lymphomas per se, nor with any signs, symptoms or laboratory findings of MPD. Moreover, JAK2V617F appeared subsequently in the peripheral blood of 2 of the 3 patients. Conclusion: These findings suggest that JAK2V617F arises in the bone marrow of individuals before clinical manifestation of any myeloid disorders. Presence of JAK2V617F in bone marrow might therefore increase the risk of future MPD development, just as monoclonal gammopathy of undetermined significance (MGUS) increases the risk of multiple myeloma. We term this phenomenon ‘JAK2V617F of undetermined significance’ (JMUS). Its clinical significance remains to be determined. To our knowledge, these findings represent the first identification of JAK2V617F in the bone marrow of patients without myeloid malignancies.
Recently, a point mutation in the JAK2 gene, JAK2 (V617F) , was discovered in several myeloid proliferative neoplasms including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Demonstration of the mutation and other similar mutations has now become one of the major criteria in the diagnosis of these neoplasms in the revised World Health Organization Classification of Tumors of Hematopoietic Tissues. In this chapter, we compared the advantages and disadvantages of five commonly used methods for the detection of JAK2 (V617F) . We explained, based on the current literature, why analytic sensitivity of the methodology is of particular importance for the detection of JAK2 (V617F) . A detailed laboratory procedure for the performance of an extensively optimized ARMS-PCR assay was presented. The assay shows distinct patterns for normal, mutant, and mixed genotypes. Diagnostically, it is highly sensitive, highly specific, and simple to perform with no need for any specialized equipment other than thermocyclers.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.